A Phase I Multi-center Study to Evaluate the Safety ,Tolerability and Efficacy of LBL-007 Combined With Toripalimab or LBL-007 Combined With Toripalimab and Axitinib Tablets in the Treatment of Unresectable or Metastatic Melanoma

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 09 Jan 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Axitinib (Primary) ; LBL-007 (Primary) ; Toripalimab (Primary)
Indications Acral lentiginous melanoma; Malignant melanoma
Focus Adverse reactions
Sponsors Nanjing Leads Biolabs

Most Recent Events

02 Jan 2024 Planned End Date changed from 20 Apr 2024 to 20 Dec 2024.
02 Jan 2024 Planned primary completion date changed from 10 Dec 2023 to 10 Aug 2024.
30 Jun 2023 According to a BeiGene media release, the study now progressing into phase II stage.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight